Only one included study used edibles. The review’s mostly inhalation-based evidence could not establish a general blood-THC relationship for all oral cannabis products.
What the review described
The edible cohort included twenty-two participants and an average consumed THC dose of 7.3 mg. Blood and simulator assessments were reported at about two hours after consumption. Significant associations between blood THC and the evaluated lateral-control measures were not demonstrated.
All other included articles investigated inhaled cannabis. The review identified this imbalance as a limitation because oral and inhaled THC have different pharmacokinetic profiles.
One dose range and time point are not every edible exposure
A result at approximately two hours after a relatively low average dose cannot characterize every earlier or later interval, high-dose product or repeated-use pattern. A nonsignificant correlation in a small cohort also does not supply a blood concentration that guarantees unimpaired driving.
Keep the route attached to the conclusion
If an opinion cites this review about an edible case, identify the oral evidence explicitly rather than allowing eleven inhalation articles to imply broad oral replication. The review supports further route-specific study. It does not provide an edible-to-smoking concentration conversion, a safe waiting period or a direct reconstruction of one driver’s performance from a delayed blood sample.
Related reading: cannabis screening and impairment.
Research cited
Behzad and colleagues (2025). Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review. DOI: 10.1093/ijnp/pyaf021.
Leave a Reply